Sema Anak

Sema Anak

Auto-generated profile, based on publicly available information

Sema Anak

Pediatric Bone Marrow Transplantation Unit, Istanbul Medipol University, Bagcilar, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2021 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
YYYöntem Yaman
Yöntem Yaman
MEMurat Elli
Murat Elli
ŞŞŞifa Şahin
Şifa Şahin
KOKursat OZDILLI
Kursat OZDILLI
HBHülya Bilgen
Hülya Bilgen
SASema Anak
Sema Anak

31 May 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
IKIbrahim Kandemir
Ibrahim Kandemir
SASema Anak
Sema Anak
SKSerap Karaman
Serap Karaman
AYAkan Yaman
Akan Yaman
MİMuhammet Ali İş
Muhammet Ali İş
ODOmer Devecioglu
Omer Devecioglu
Background: The study investigates the nutritional status in children with acute lymphoblastic leukemia (ALL) during chemotherapy treatment because nourishment is substantial, as much as chemotherapy in children with malignant diseases. Material and Method: We enrolled 17 children with ALL (between 1 to 16 year-old, mean age 6.03 ± 4.04 y) from 5 different centers in Istanbul between September 2013 and May 2014. Anthropometric data, prealbumin, B12, and folate levels were assessed, at diagnosis, after the induction phase of chemotherapy, and before maintenance phases of chemotherapy in a longitudinal and prospective study. Results: Patients remarkably lost weight at the end of the induction phase (P=0.064) and regained this loss before maintenance chemotherapy (P=0.001). At the end of induction chemotherapy serum prealbumin level (P=0.002), weight for height ratios (P=0.016), weight for age ratios (P=0.019) significantly decreased. From the end of the induction phase to the beginning of maintenance chemotherapy, weight (P=0.001) and weight for age (P=0.017) significantly, and weight for height were remarkably elevated (P=0.076). At the end of the induction phase, serum prealbumin levels were significantly lower (P=0.048) and below laboratory reference values (P=0.009) in children younger than 60 months compared with those older. Serum folate levels increased from the end of the induction phase to the beginning of the maintenance phase (P=0.025). Serum vitamin B12 levels did not alter significantly. Conclusion: There is malnutrition risk at the end of the induction phase of the ALL-BFM chemotherapy regimen; therefore, clinicians should follow up on nutrition closely, especially in under 5-year-old patients. However, before the beginning of the maintenance phase, children start to gain weight, and obesity risk occurs. Thus, further studies are needed to evaluate nutritional status during childhood ALL chemotherapy.


8 July 2008 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
YBYasemin Isik Balci
Yasemin Isik Balci
TTTuba Turul
Tuba Turul
GDGhaniya Daar
Ghaniya Daar
SASema Anak
Sema Anak
ODOmer Devecioglu
Omer Devecioglu
DCDuygu Uckan Cetinkaya
Duygu Uckan Cetinkaya

11 November 2024 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
NBNihan Bayram
Nihan Bayram
YYYontem Yaman
Yontem Yaman
KOKursat OZDILLI
Kursat OZDILLI
SNSerdar Nepesov
Serdar Nepesov
IAIsik Odaman Al
Isik Odaman Al
SASema Anak
Sema Anak
Introduction: Thrombocytopenia is a common clinical problem in cancer patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). It can occur as prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) and may cause potentially fatal bleeding. However, data on the treatment of post-transplant thrombocytopenia is still lacking. Methods: We reported our practices involving 15 pediatric patients who received eltrombopag (ELT) treatment for PIT and SFPR after autologous HSCT. Results: The overall response was 78.5% (11/14), with 1 patient excluded due to noncompliance. The 12 surviving patients' median follow up was 699 days (range: 167 to 2250 d). Conclusions: Our study indicates the efficacy and safety of ELT for treating PIT and SFPR after autologous HSCT in pediatric patients. However, more studies are needed to confirm these findings in children.

1 July 2022 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
SNSerdar Nepesov
Serdar Nepesov
YYYöntem Yaman
Yöntem Yaman
MEMurat Elli
Murat Elli
NBNihan Bayram
Nihan Bayram
KOKursat OZDILLI
Kursat OZDILLI
SASema Anak
Sema Anak
Objective: In this study, we sought to describe the clinical, laboratory, and genetic character- istics of patients diagnosed with primary hemophagocytic lymphohistiocytosis. Thus, we aimed to evaluate the early diagnosis and appropriate treatment options for pediatric hemophago- cytic lymphohistiocytosis patients. Materials and Methods: Medical records of 9 patients diagnosed with primary hemophago- cytic lymphohistiocytosis between November 2013 and December 2019 were analyzed retro- spectively. Clinical, genetic, and laboratory characteristics, family histories, initial complaints, physical examination findings, age at diagnosis, treatment choices, and clinical follow-up of all patients were investigated. Results: The mean age at diagnosis was 11 months (range: 1.5 months to 17 years). Genetic analysis was performed in all patients, and a disease-related mutation was detected in 8 (89%) of them. Among clinical features, 6 (66%) patients had fever, 5 (56%) had splenomegaly, 4 (44%) had lymphadenopathy, 4 (44%) had skin rash, and 4 (44%) had neurological findings. Hemophagocytosis was observed in the bone marrow samples of 6 (66%) patients. Disease remission was achieved in 7 (78%) patients. Hematopoietic stem cell transplantation was per- formed in 7 (78%) patients. Conclusion: Hemophagocytic lymphohistiocytosis may present with different clinical symptoms that can cause a significant diagnostic delay. The only curative treatment option in primary hemophagocytic lymphohistiocytosis patients is hematopoietic stem cell transplantation. The chemotherapy should be started as early as possible, in order to achieve a disease remission. Patients should be referred to the appropriate bone marrow transplant center for hematopoi- etic stem cell transplantation as soon as they reach the disease remission. Cite this article as: Nepesov S, Yaman Y, Elli M, et al. Clinical, genetic, and outcome characteristics of pediatric patients with primary hemophagocytic lymphohistiocytosis. Turk Arch Pediatr. 2022;57(4):398-405.